In 54 patients presenting for electroconvulsive therapy, the concentration of serum potassium was measured before and after the induced convulsion modified with a standard anaesthetic technique of methohexitone and suxamethonium. It was found that there was a statistically significant rise in serum potassium, but that the duration of convulsion had no significant effect on that rise in serum potassium. In a further 11 patients, methohexitone alone was administered without ECT, and it was found that serum potassium fell. Methohexitone, suxamethonium and ECT in combination cause a rise in serum potassium which is not clinically important unless pre-induction level is abnormally high, and prolonged convulsion does not exaggerate this rise.
INTRODUCTION
Electroconvulsive therapy (ECT) has been used in the management of various psychiatric disorders for over 50 years. More recently, the tonic/clonic convulsion induced by this therapy has been modified by the use of suxamethonium. It is well documented that suxamethonium causes increases in serum potassium,' and at first sight it might be expected that the combination of suxamethonium fasciculation and the modified tonic/clonic convulsion induced by ECT would cause a more exaggerated rise in the level of serum potassium than that produced by suxamethonium alone. However, several studies have shown that the rise produced by the combination is rarely of clinical significance.2 3,4,5 These authors did not examine the possible link between duration of fit and the subsequent elevation in serum potassium. The aim of this study was to examine the relationship between serum potassium changes and the duration of the tonic/clonic convulsion using a standard anaesthetic technique.
METHODS
Fifty -four unpremedicated, ASA grade I and 11 patients, presenting for elective ECT were studied. Research Ethical Committee approval was obtained, and patients gave informed verbal consent. An indwelling 21 gauge needle was inserted on the dorsum of both hands (one for the administration of anaesthetic drugs, one for blood sampling). A sample of blood was obtained for basal ECT and serum potassium serum potassium measurement, and then induction was achieved with 1mg/kg methohexitone, followed by 0*5mg/kg suxamethonium. The lungs were manually inflated with oxygen, and ECT given 15 to 20 seconds after suxamethonium fasciculation. A further sample of blood for potassium was withdrawn 120 seconds after drug administration without venous occlusion. The duration of the tonic/clonic convulsion was timed. In a further 11 patients, methohexitone 1 mg/kg alone was administered (ie no suxamethonium and no ECT) as part of their normal therapy in this hospital. Blood samples were obtained before and 120 seconds after methohexitone administration. Those samples not immediately analysed were stored at 40C for a maximum of four hours. Potassium concentrations were determined using a Corning 480 flame photometer after visually ensuring the absence of haemolysis by an independent laboratory technician (those showing haemolysis were excluded from the study). Based on precision of routine quality control, changes in excess of 0-1 mmol/1 were considered significant. Results were analysed statistically using the Wilcoxon signed rank test and correlation coefficient (Table) . 
DISCUSSION
The results of this study confirm that small but statistically significant increases in serum potassium occur after ECT modified by suxamethonium in the majority of patients. The maximum rise was 0 4 mmol/l, and is unlikely to be of clinical significance unless the pre-anaesthetic level is above the upper normal value. Wide variation in the duration of modified convulsion was observed, ranging from 0 to 55 seconds, with only a weakly negative correlation to subsequent alteration in serum potassium. This tends to support the view of Bali 2 that the convulsion pumps the muscle venous blood which is rich in potassium following suxamethonium fasciculation into the general circulation, without causing hyperkalaemia by itself. Pilditch and Baker3 have also shown that the grade of convulsion, using an arbitrary grading system, produced no significant differences in serum potassium. Methohexitone was used as the induction agent in this study as the majority of patients attended as day patients. Eleven patients received methohexitone alone, with no ECT. Potassium levels in these patients fell, demonstrating the protective effect against large rises in serum potassium noted by other authors, which applies also to thiopentone. 6 This study confirms that small rises in serum potassium follow the use of methohexitone and suxamethonium for ECT. There does not appear to be any consistent relationship between the duration of the convulsion and the subsequent change in serum potassium in normal patients. In addition, methohexitone appears to attenuate the rise in serum K + associated with the modified convulsion of ECT.
